A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Stacey ZahlerMitchell S Cairo

Abstract

Myeloablative conditioning and allogeneic hematopoietic stem cell transplant (alloHSCT) in children with acute myeloid leukemia (AML) in first complete remission (CR1) may be associated with significant acute toxicity and late effects. Reduced-intensity conditioning (RIC) and alloHSCT in children is safe, feasible, and may be associated with less adverse effects. Gemtuzumab ozogamicin (GO) induces a response in 30% of patients with CD33+ relapsed/refractory AML. The dose of GO is significantly lower when combined with chemotherapy. We examined the feasibility and toxicity of RIC alloHSCT followed by GO targeted immunotherapy in children with CD33+ AML in CR1/CR2. Conditioning consisted of fludarabine 30 mg/m2 × 6 days, busulfan 3.2 to 4 mg/kg × 2 days ± rabbit antithymocyte globulin 2 mg/kg × 4 days followed by alloHSCT from matched related/unrelated donors. GO was administered ≥60 days after alloHSCT in 2 doses (8 weeks apart), following a dose-escalation design (4.5, 6, 7.5, and 9 mg/m2). Fourteen patients with average risk AML received RIC alloHSCT and post-GO consolidation: median age 13.5 years at transplant (range, 1 to 21), male-to-female 8:6, and disease status at alloHSCT 11 CR1 and 3 CR2. Eleven patients received allo...Continue Reading

References

Apr 13, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ifeyinwa OsunkwoMitchell S Cairo
Oct 6, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Elizabeth RomanMitchell S Cairo
Mar 16, 2006·Blood·UNKNOWN Children's Oncology GroupStella M Davies
Apr 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hélène LapillonneJudith Landman-Parker
Apr 5, 2007·The Oncologist·Soheil Meshinchi, Robert J Arceci
May 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard AplencUNKNOWN Children's Oncology Group
Sep 24, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Tang-Her JaingPei-Kwei Tsay
Oct 20, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Monica BhatiaMitchell S Cairo
Dec 10, 2009·British Journal of Haematology·Christian M ZwaanUNKNOWN International BFM Study Group on Paediatric AML
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John T HoranMarcelo C Pasquini
Sep 21, 2011·Expert Review of Anticancer Therapy·Carmelo RizzariValentino Conter
Aug 14, 2012·British Journal of Haematology·Matthew BarthMitchell S Cairo
Dec 21, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Prakash SatwaniMitchell S Cairo
Sep 17, 2013·British Journal of Haematology·Mohamed A Kharfan-DabajaAmbuj Kumar
Sep 23, 2014·Journal of Cancer Research and Clinical Oncology·Caroline WoehleckeBernd Gruhn

❮ Previous
Next ❯

Citations

Sep 26, 2017·Expert Opinion on Biological Therapy·Challice L BonifantStephen Gottschalk
Dec 19, 2019·Current Opinion in Pediatrics·Challice L Bonifant, Sarah K Tasian
Aug 28, 2020·Frontiers in Immunology·Lia WalcherUta Kossatz-Boehlert
Dec 6, 2019·Frontiers in Pediatrics·Annalisa LonettiRiccardo Masetti
Oct 21, 2020·Journal for Immunotherapy of Cancer·Michael M BoyiadzisMartin S Tallman
Sep 22, 2020·Minerva medica·MIchele GottardiClaudio Cerchione

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

© 2022 Meta ULC. All rights reserved